La vendita allo scoperto per JELD-WEN Holding dà agli investitori un'idea del grado in cui gli investitori stanno scommettendo sul declino delle azioni di JELD-WEN Holding. I dati relativi alle vendite allo scoperto vengono aggiornati ogni due settimane.

JELD-WEN Holding (NYSE:JELD) Azioni, Report sulle vendite allo scoperto

JELD-WEN Holding

JELD-WEN Holding Inc is engaged in door and window manufacturing. The company designs, produces, and distributes interior and exterior building products, offering a selection of doors, windows, walls, and related products. The products are used in the new construction of residential single and multi-family homes and non-residential buildings. The firm's operating segments are North America, Europe, and Australasia. It generates a majority of its revenue from North America.

JELD-WEN Holding Inc

Needham analyst Kyle Peterson reiterates SoFi Technologies (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SOFI#NASDAQ">SOFI</a>) with a Buy and maintains $20 price target.

News

Price Target

Reiteration

Analyst Ratings

SOFI

Needham Reiterates Buy on SoFi Technologies, Maintains $20 Price Target

As of April 30, 2025, two stocks in the materials sector could be flashing a real warning to investors who value momentum as a key criteria in their trading decisions.
The RSI is a momentum indicator, which compares a stock&#8217;s strength on days when prices go up to its strength on days when prices go down. When compared to a stock&#8217;s price action, it can give traders a better sense of how a stock may perform in the short term. An asset is typically considered overbought when the <a href="https://www.benzinga.com/topic/rsi">RSI is above 70</a>, according to <a href="https://pro.benzinga.com/">Benzinga Pro</a>. 
Here's the latest list of major overbought players in this sector.
<h3 class="wp-block-heading">Sensient Technologies Corp (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SXT#NYSE">SXT</a>)</h3>
<ul>
<li>On April 25, Sensient Technologies reported better-than-expected first-quarter financial results and raised its FY25 EPS forecast. &#8220;As expected, Sensient got off to a strong start in the first quarter of 2025, building on the momentum from the previous year. Our results are driven by solid volume growth and sales wins, particularly in natural colors. The quarter&#8217;s achievements underscore our ability to adapt in dynamic market conditions, and I am pleased to reaffirm our 2025 guidance,&#8221; said Paul Manning, Sensient&#8217;s Chairman, President, and Chief Executive Officer. The company's stock jumped around 27% over the past month and has a 52-week high of $94.64.</li>
<li>RSI Value: 85.2&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</li>
<li>SXT Price Action: Shares of Sensient jumped 4.6% to close at $94.34 on Tuesday.</li>
<li>Edge Stock Ratings: 87.99 Momentum score with Value at 54.19. </li>
</ul>
<figure class="wp-block-image size-full is-resized"><a href="https://www.benzinga.com/quote/sxt"><img loading="lazy" decoding="async" width="493" height="180" src="https://editorial-assets.benzinga.com/wp-content/uploads/2025/04/30042127/image-227.png" alt="" class="wp-image-894312" style="width:414px;height:auto" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2025/04/30042127/image-227.png 493w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/04/30042127/image-227-300x110.png 300w" sizes="(max-width: 493px) 100vw, 493px" /></a></figure>
<h3 class="wp-block-heading">Compass Minerals International, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CMP#NYSE">CMP</a>)</h3>
<ul>
<li>On March 25, Compass Minerals announced cost structure reductions to align with current business needs. &#8220;Decisions such as these are never easy, but our board of directors and senior leadership team took a hard look at our cost structure and determined these actions were necessary to enable us to generate additional cash flow and accelerate our deleveraging,&#8221; said Edward C. Dowling Jr, president and CEO. The company's stock gained around 43% over the past month and <a href="https://www.benzinga.com/quote/CMP">has a 52-week high</a> of $15.82.</li>
<li>RSI Value: 80.7</li>
<li>CMP Price Action: Shares of Compass Minerals gained 2% to close at $13.26 on Tuesday.</li>
</ul>
Curious about other BZ Edge Rankings? Click here to discover <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-2#:~:text=Turn%20Market%20Chaos,when%20markets%20rebound">how similar stocks measure up</a>. 
Read This Next: 
<ul>
<li><a href="https://www.benzinga.com/25/04/45064976/top-3-industrials-stocks-which-could-rescue-your-portfolio-in-q2">Top 3 Industrials Stocks Which Could Rescue Your Portfolio In Q2</a> </li>
</ul>
Photo via Shutterstock

Short Ideas

Pre-Market Outlook

Markets

Trading Ideas

Top 2 Materials Stocks That May Fall Off A Cliff This Quarter

WIIM

DTCK

Davis Commodities shares are trading higher after the company entered a strategic joint venture with a Malaysian agri-processor to produce and export to the Northeast Asian market.

Jaguar to host investor webcast today at 8:30 AM Eastern to review the initial results from the proof-of-concept study of crofelemer for MVID and SBS-IF presented April 26 at the <a href="https://pr.report/9xgt">Annual ELITE PED-GI Congress</a>; Click <a href="https://pr.report/9xgu">here</a> to register
There are no approved drug treatments for MVID, an ultrarare pediatric disease characterized by severe diarrhea and malabsorption that requires intensive parenteral support for nutritional and fluid management including total parenteral nutrition (TPN) - which carries the risk of morbidity, infections, metabolic complications, liver and kidney problems, and neurodevelopmental delay
This proof-of-concept data in MVID supports crofelemer's potential inclusion in the European Medicines Agency's (EMA) <a href="https://pr.report/9xgv">PRIME</a> program for expediated and assisted regulatory approval in the EU as well as FDA's <a href="https://pr.report/9xgw">Breakthrough Therapies</a> program for expedited regulatory approval in the US
SAN FRANCISCO, CA / <a href="https://www.accessnewswire.com/">ACCESS Newswire</a> / April 30, 2025 / <a href="https://pr.report/9xgb">Jaguar Health, Inc.</a> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/JAGX#NASDAQ">JAGX</a>) (Jaguar) family companies <a href="https://pr.report/9xgd">Napo Pharmaceuticals</a> (Napo) and <a href="https://pr.report/9xge">Napo Therapeutics</a> today announced initial proof-of-concept results showing that a novel liquid formulation of crofelemer reduced the required TPN and/or supplementary intravenous fluids, collectively referred to as parenteral support (PS) in patients with intestinal failure due to microvillus inclusion disease (MVID) and short bowel syndrome (SBS-IF) by up to 27% and 12.5% respectively. In addition, this data showed that crofelemer reduced stool volume output and/or frequency of watery stools, and increased urine output - an indicator of improved nutrient oral absorption.

JAGX

Jaguar Health Reports Encouraging Proof-of-Concept Results For Crofelemer In MVID And SBS-IF Patients

SAGT

Sagtec Global shares are trading higher after the company reported a year-over-year increase in FY24 financial results.

Initial trial phase ("PoC 1") achieved key learnings and met all study objectives
Clinically meaningful pain reduction with 100% of responders achieving zero opioid use at 7 days post-procedure and 73% of responders remaining opioid free at 4-6 week follow-up
Company has initiated market expansion study ("PoC 2") of additional visceral cancers, and earlier stage pancreatic cancer, to begin in Q2 2025
Additional indications potentially double the addressable market beyond pancreatic cancer pain
&nbsp;

Biotech

General

AMIX

Autonomix Medical Reports Outcomes In Initial Phase Of First-in-Human Proof-of-Concept Trial In Pancreatic Cancer Pain And Initiates Market Expansion Study for Visceral Cancer Pain

Needham analyst Ami Fadia reiterates Sage Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SAGE#NASDAQ">SAGE</a>) from Hold to Hold.

SAGE

Needham Reiterates Hold on Sage Therapeuticsto Hold

PPBT

Purple Biotech shares are trading higher after the company's CM24 showed up to a 90% reduction in the death risk for pancreatic cancer patients and announced it will commence a Phase 2b study.

Earnings

Sagtec Global FY24 EPS $0.14 Up From $0.09 YoY; Revenue $11.6M Up From $6.5M YoY

Ocean Power Technologies, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/OPTT#NYSE">OPTT</a>) ("OPT" or the "Company"), a leader in innovative, cost-effective, low-carbon and artificial intelligence maritime services that enable safer and more productive ocean operations and related power, data, and service solutions, today announced the shipment of a WAM-V&#xAE; 22' with autonomous capabilities designed to provide offshore surveys with 24/7 operational payloads for multiple days without requiring a return to base.

OPTT

Ocean Power Technologies Ships Autonomous WAM-V 22 For Multi-Day Offshore Surveys

CERo Therapeutics Holdings, Inc., (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CERO#NASDAQ">CERO</a>) ("CERo" or the "Company") an innovative immunotherapy company seeking to advance the next generation of engineered T cell therapeutics that employ phagocytic mechanisms, announces that TriStar Centennial Medical Center, through Sarah Cannon Research Institute (SCRI), in Nashville, Tennessee, is a clinical trial site for the Company's Phase 1 clinical of CER-1236. Collaborating with SCRI to advance cancer research, TriStar Centennial offers innovative clinical research trials for various disease indications. The trial is focused on patients with acute myeloid leukemia (AML), and patient enrollment is underway, with expected dosing of the first patient during the first half of 2025.&nbsp;

CERO

CERo Therapeutics Announces TriStar Centennial Medical Center As Clinical Trial Site For Phase 1 Clinical Of CER-1236

RCKY

Rocky Brands shares are trading higher after the company reported better-than-expected Q1 financial results.

Telsey Advisory Group analyst Joseph Feldman maintains Holley (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/HLLY#NYSE">HLLY</a>) with a Outperform and maintains $4.5 price target.

HLLY

Telsey Advisory Group Maintains Outperform on Holley, Maintains $4.5 Price Target

Western Digital Declares Quarterly Dividend Of $0.10 Per Share Of The Company's Common Stock, Payable On June 18 To Shareholders Of Record As Of June 4

U.S. stock futures were mixed this morning, with the Dow futures gaining around 0.1% on Wednesday.
Shares of Starbucks Corporation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SBUX#NASDAQ">SBUX</a>) fell sharply in today's pre-market trading as the company reported weaker-than-expected <a href="https://www.benzinga.com/25/04/45090652/starbucks-says-simple-everyday-luxury-is-here-to-stay-as-people-still-want-small-indulgences-amid-belt-tightening">second-quarter financial results</a>.
The coffee giant reported second-quarter adjusted earnings of 41 cents per share, missing analyst estimates of 50 cents per share.
Starbucks shares dipped 6.5% to $79.33 in the pre-market trading session.
Here are some other stocks moving lower in pre-market trading.
<ul>
<li>InnovAge Holding Corp. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/INNV#NASDAQ">INNV</a>) shares dipped 17.4% to $2.52 in pre-market trading. InnovAge will announce fiscal third quarter 2025 financial results and host conference call Tuesday, May 6.</li>
<li>Tenable Holdings, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TENB#NASDAQ">TENB</a>) shares fell 17% to $27.95 in pre-market trading after the company cut its FY25 sales guidance.</li>
<li>Super Micro Computer, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SMCI#NASDAQ">SMCI</a>) declined 15.1% to $30.57 in pre-market trading after the company lowered its preliminary guidance.</li>
<li>Snap Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SNAP#NYSE">SNAP</a>) dipped 13.5% to $7.87 in pre-market trading as the company reported first-quarter financial results and announced it will not provide second-quarter guidance.</li>
<li>Wabash National Corporation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/WNC#NYSE">WNC</a>) fell 13.3% to $8.64 in pre-market trading following weaker-than-expected quarterly results.</li>
<li>First Solar, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/FSLR#NASDAQ">FSLR</a>) dipped 13.1% to $119.25 in pre-market trading after the company reported worse-than-expected first-quarter EPS results and cut its FY25 guidance.</li>
<li>Unum Group (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/UNM#NYSE">UNM</a>) tumbled 9.1% to $72.00 in pre-market trading after the company reported worse-than-expected first-quarter financial results.</li>
<li>Vicor Corporation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VICR#NASDAQ">VICR</a>) fell 7.3% to $48.12 in pre-market trading after the company reported worse-than-expected first-quarter financial results.</li>
<li>Garmin Ltd. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GRMN#NASDAQ">GRMN</a>) declined 5.4% to $193.00 in pre-market trading after posting weak earnings.</li>
<li>Bausch + Lomb Corporation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BLCO#NYSE">BLCO</a>) fell 5.3% to $12.99 in pre-market trading following downbeat first-quarter results.</li>
</ul>
Now Read This: 
<ul>
<li><a href="https://www.benzinga.com/25/04/45064976/top-3-industrials-stocks-which-could-rescue-your-portfolio-in-q2">Top 3 Industrials Stocks Which Could Rescue Your Portfolio In Q2</a> </li>
</ul>
Photo via Shutterstock

Movers

BLCO

FSLR

GRMN

INNV

SBUX

SMCI

SNAP

TENB

VICR

Starbucks Posts Weak Earnings, Joins Super Micro Computer, Snap And Other Big Stocks Moving Lower In Wednesday's Pre-Market Session

IMUX

Immunic shares are trading lower. The company reported Phase 2 data from its CALLIPER trial.

Blue Foundry (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BLFY#NASDAQ">BLFY</a>) reported quarterly losses of $(0.13) per share which beat the analyst consensus estimate of $(0.17) by 23.53 percent. This is unchanged from the same period last year. The company reported quarterly sales of $11.14 million which beat the analyst consensus estimate of $10.29 million by 8.20 percent. This is a 12.87 percent increase over sales of $9.87 million the same period last year.

Earnings Beats

BLFY

Blue Foundry Q1 EPS $(0.13) Beats $(0.17) Estimate, Sales $11.14M Beat $10.29M Estimate

AIMD

AIMDW

Ainos Partners With ASE Chung Li To Power AI Scent Digitization In Smart Manufacturing

Western Digital (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/WDC#NASDAQ">WDC</a>) is looking for Q4 Adj EPS of $1.25-$1.65 vs $1.16 analyst estimate. sees sales of $2.300 billion-$2.600 billion vs $2.39 billion analyst estimate.

Guidance

Western Digital Sees Q4 Adj EPS $1.25-$1.65 vs $1.16 Est; Sees Sales $2.300B-$2.600B vs $2.39B Est

STSS

Sharps Technology shares are trading higher after the company announced it received a $400K initial purchase order from an IV flushing solutions business.

Press Releases

JELD-WEN Completes Redemption of Senior Notes

JELD-WEN to Release Third Quarter 2024 Results

JELD-WEN Reports Third Quarter 2024 Results

Contracts

JELD-WEN Announces Purchase Agreement for Towanda, PA Facility as a Result of Court-Ordered Divestiture Process

JELD-WEN to Release Fourth Quarter 2024 Results

JELD-WEN Completes Sale of Towanda, PA Facility as a Result of Court-Ordered Divestiture Process

JELD-WEN Reports Fourth Quarter and Full Year 2024 Results

JELD-WEN to Release First Quarter 2025 Results

Commodities

JELD-WEN Named One of 'America's Climate Leaders' by USA TODAY

JELD-WEN Recognized on 'Most Trustworthy Companies in America' List for Fourth Consecutive Year

Comments

JELD-WEN Holding

Vendite allo scoperto

JELD-WEN Holding (NYSE:JELD) Azioni, Report sulle vendite allo scoperto

Le persone guardano anche

Notizie

PARTNER/COLLABORATORE

BENZINGA NEL MONDO